Latest Biotech News

Eyepoint’s Phase 3 LUGANO results for Duravyu fell short of its primary goal against Eylea aflibercept in wet age-related macular degeneration, pushing the company to reassess its regulatory path....

A U.S. court cleared the path for a lawsuit alleging Bristol Myers Squibb delayed FDA approval of Breyanzi, tying the dispute to milestone payment dynamics from its 2019 Celgene acquisition. The...

AstraZeneca terminated a Phase 3 lung cancer trial of volrustomig after an interim data check indicated survival targets were unlikely to be met versus an active comparator, according to the...

Slate Medicines agreed to combine with Fulcrum Therapeutics in a reverse merger, setting up a move onto Nasdaq alongside a $245 million financing for its migraine pipeline. Fulcrum’s programs were...

Leo Pharma struck a licensing deal with Japan’s Tanabe Pharma for an oral drug targeting two genetic light-sensitive skin diseases, with total payments up to $435 million including upfront and...

Pharma companies are accelerating investment in AI infrastructure and reasoning workflows designed to connect large integrated datasets (genomics to metabolomics) into end-to-end drug discovery...

Argenx’s Phase 3 myositis subgroup readout was complemented by broader immunotherapy R&D that increasingly emphasizes more targeted engineering and delivery constraints. In another preclinical...

A study in Nature Communications reported that next-generation sequencing approaches can detect residual disease in T-cell acute lymphoblastic leukemia, addressing a key need for sensitive...

New proposals aimed at speeding first-in-human timelines focused on reducing unnecessary pre-IND work and clarifying streamlined data generation for early clinical research. Coverage framed the...

Tagomics described a new cell-free DNA blood-test approach for multi-organ drug safety monitoring using its LiquiPath platform, built around tagging and enriching unmethylated genomic regions. The...

Eyepoint’s pivotal results for its wet age-related macular degeneration drug Duravyu underperformed expectations in an Eyepoint-sponsored Phase 3 program, with patients failing to maintain vision...

Argenx reported that Vyvgart Hytrulo, a subcutaneous FcRn antagonist formulation, met a key Phase 3 endpoint in immune-mediated necrotizing myopathy (IMNM), delivering rapid and sustained benefit...

AstraZeneca moved to cancel a Phase 3 lung cancer trial of volrustomig after an interim look indicated the therapy was unlikely to achieve survival endpoints versus an existing comparator. The...

A court cleared the path for a suit accusing Bristol Myers Squibb of delaying FDA approval of Breyanzi, a gene therapy for non-Hodgkin lymphoma. The claim ties the alleged slow-walk to...

Physicians and professional groups warned that proposed US changes to federal research grant allocation could shift peer review toward a pre-issuance political screen tied to administration...

University of Pittsburgh physician-scientists reported JAMA results from an adaptive clinical trial suggesting that refrigerated, cold-stored platelets can safely extend product availability to 21...

Integrated DNA Technologies (IDT) showcased a new CRISPR off-target site nomination method designed to streamline discovery-to-confirmation by boosting high-confidence targets and reducing...

Slate Medicines is moving toward Nasdaq through a reverse merger with Fulcrum Therapeutics, backed by a $245M financing aimed at advancing migraine programs. The combined plan includes pushing a...

Janssen Biotech discontinued development of Abelzeta Pharma’s C-CAR039, a CD20/CD19 bispecific CAR T therapy, and Abelzeta regained all rights to the asset. The discontinuation resets commercial...

A randomized Phase 2 RadiCaL trial (Alliance A031801) reported that adding radium-223 to cabozantinib did not prevent serious bone complications in advanced kidney cancer, despite producing a...